Stock JNJ JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Johnson & Johnson NEO Exchange

Equities

JNJ

CA47817E1034

End-of-day quote NEO Exchange
Other stock markets
 18:00:00 2024-06-06 EDT 		5-day change 1st Jan Change
19.75 CAD +0.61% Intraday chart for Johnson & Johnson +0.41% -6.62%
06-08 Top law firms in US opioid lawsuits to get hundreds of millions in fees RE
06-07 J&J-backed Rapport Therapeutics shares debut nearly 6% higher RE

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.62% 354B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 632B
B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
A+
NOVARTIS AG Stock Novartis AG
+11.88% 216B
B-
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-0.73% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. JNJ Stock
  5. Ratings Johnson & Johnson